Tom 8, Nr 3 (2022)
Artykuł przeglądowy
Opublikowany online: 2020-12-31
Wyświetlenia strony
4838
Wyświetlenia/pobrania artykułu
893
Ewolucja w leczeniu raka gruczołu krokowego. Część 1
Onkol Prakt Klin Edu 2022;8(3):165-177.
Streszczenie
Rak gruczołu krokowego jest najczęstszym nowotworem występującym u mężczyzn. W leczeniu chorych od dawna wykorzystuje się strategie oparte na deprywacji androgenowej. Wyzwaniem pozostaje terapia w przypadku choroby opornej na kastrację. W ciągu ostatniego dwudziestolecia opcje leczenia systemowego chorych na ten nowotwór intensywnie ewoluowały. Nowe cząsteczki, o niespotykanej wcześniej aktywności, znacząco poprawiły przeżycie chorych z zaawansowaną postacią choroby.
W niniejszym opracowaniu przedstawiono kluczowe aspekty ewolucji leczenia systemowego raka gruczołu krokowego w ciągu ostatnich dekad. W pierwszej części autorzy skupili się na terapiach skutecznych w fazie oporności na kastrację. W drugiej części zostaną opisane dane dotyczące wcześniejszych linii leczenia oraz zasady doboru optymalnej sekwencji terapii.
Słowa kluczowe: rak gruczołu krokowegooporny na kastracjęmCRPCabirateronapalutamidenzalutamid
Referencje
- Adams J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet. 1853; 1(1): 393.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
- White JW. II. The Present Position of the Surgery of the Hypertrophied Prostate. Ann Surg. 1893; 18(2): 152–188.
- Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4): 232–240.
- Mainwaring WI. A soluble androgen receptor in the cytoplasm of the male mastomys prostate. Urol Res. 1978; 6(1): 29–33.
- Schally AV, Kastin AJ, Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril. 1971; 22(11): 703–721.
- Messner EA, Steele TM, Tsamouri MM, et al. The androgen receptor in prostate cancer: Effect of structure, ligands and spliced variants on therapy. Biomedicines. 2020; 8(10).
- Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012; 72(18): 4611–4615.
- Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011; 8(1): 12–23.
- Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991; 83(4): 288–291.
- Bai S, Zhang BY, Dong Y. Impact of taxanes on androgen receptor signaling. Asian J Androl. 2019; 21(3): 249–252.
- Tannock I, Wit Rde, Berry W, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 2004; 351(15): 1502–1512.
- Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242–245.
- Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009; 15(2): 723–730.
- Bono Jde, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010; 376(9747): 1147–1154.
- de Wit R, de Bono J, Sternberg CN, et al. CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(26): 2506–2518.
- Fizazi K, Scher H, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2012; 13(10): 983–992.
- Attard G, Borre M, Gurney H, et al. PLATO collaborators. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018; 36(25): 2639–2646.
- Morris M, Heller G, Bryce A, et al. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2019; 37(15_suppl): 5008–5008.
- Scher HI, Fizazi K, Saad F, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187–1197.
- Beer TM, Armstrong AJ, Rathkopf DE, et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5): 424–433.
- Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol. 2017; 71(2): 151–154.
- Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016; 70(6): 963–970.
- Fizazi K, Massard C, Bono P, et al. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Eur Urol Focus. 2017; 3(6): 606–614.
- Sgouros G, Hobbs R, Josefsson A. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides. Curr Radiopharm. 2018; 11(3): 209–214.
- Godlewski T. A new radio-active product from actinium. Nature. 1905; 71(1839): 294–295.
- Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019; 16(12): 745–756.
- Parker C, Nilsson S, Heinrich D, et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213–223.
- Parker CC, Coleman RE, Sartor O, et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018; 73(3): 427–435.
- Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19): 3089–3094.
- Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411–422.
- Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017; 35(1): 40–47.
- Kwon ED, Drake CG, Scher HI. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15(7): 700–712.
- Antonarakis E, Piulats J, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020; 38(5): 395–405.
- Bergerot P, Lamb P, Wang E, et al. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. Mol Cancer Ther. 2019; 18(12): 2185–2193.
- Agarwal N, Loriot Y, McGregor B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. J Clin Oncol. 2020; 38(15_suppl): 5564–5564.
- Armenia J, Wankowicz SAM, Liu D, et al. PCF/SU2C International Prostate Cancer Dream Team. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018; 50(5): 645–651.
- Bono Jde, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM. 2020; 382(22): 2091–2102.
- Smith M, Sandhu S, Kelly W, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. J Clin Oncol. 2019; 37(7_suppl): 202–202.
